KALLIKREIN-RELATED PEPTIDASE 4 (KLK4)-A POTENTIAL BIOMARKER IN PROSTATE CANCER
Tumour Biol
2010
31 1
S62-S63
X-Linked Thrombocytopenia (XLT) Due to WAS Mutations: Clinical Characteristics, Long-Term Outcome, and Treatment Options
Clin Immunol
2010
135
2
15 -
Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.
Cancer Epidemiol Biomarkers Prev
2010
19
9
2143-51
The human fibrinolytic system is a target for proteases secreted by the pathogenic bacterium
J Thromb Haemost
2010
8
8-8
Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma.
Histopathology
2010
57
3
461-71
Analyzing the protease web in skin: meprin metalloproteases are activated specifically by KLK4, 5 and 8 vice versa leading to processing of proKLK7 thereby triggering its activation.
Biol Chem
2010
391
4
455-60
Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.
Br J Cancer
2010
102
4
731-7
Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).
Biochimie
2010
92
11
1546-67
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Expert Rev Mol Diagn
2010
10
7
947-62
Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells.
Am J Pathol
2010
176
3
1452-61